Abstract |
To determine the efficacy and safety of single-dose oral ciprofloxacin prophylaxis for the prevention of post-operative bacteriuria following transurethral resection of the prostate or bladder tumour, a prospective, randomized, double-blind, placebo-controlled trial was conducted. Five hundred and eighteen patients were randomized in a 2:2:1 ratio to receive ciprofloxacin 500 mg, cefotaxime 1 g or placebo 30-90 min before surgery. Of the 368 efficacy-evaluable patients, five (3.3%) ciprofloxacin, seven (4.8%) cefotaxime and five (7.0%) placebo recipients had post-operative bacteriuria (> or = 10(4) cfu/mL) during post-operative days 2-15. Five (3.4%) ciprofloxacin, five (3.4%) cefotaxime and one (2.4%) placebo recipients were considered clinical failures, of whom one, two and one patients, respectively, had concomitant bacteriuria. Drug-related adverse events were reported in six of 204 (3%) ciprofloxacin, 12 of 197 (6%) cefotaxime and one of 101 (1%) placebo patients. The observed rates of post-operative bacteriuria suggest that a single 500 mg dose of ciprofloxacin is suitable prophylaxis for transurethral surgery.
|
Authors | I W Klimberg, G H Malek, C E Cox, A L Patterson, E Whalen, S F Kowalsky, R M Echols |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 43 Suppl A
Pg. 77-84
(Mar 1999)
ISSN: 0305-7453 [Print] England |
PMID | 10225576
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Cephalosporins
- Placebos
- Ciprofloxacin
- Cefotaxime
|
Topics |
- Administration, Oral
- Adult
- Aged
- Anti-Infective Agents
(therapeutic use)
- Bacteriuria
(prevention & control)
- Cefotaxime
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Ciprofloxacin
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Placebos
- Prostatectomy
(adverse effects)
|